Sonja Anlauf

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Aicuris Gmbh + Co. Kg., Bayer Intellectual Property Gmbh, Bayer Pharma Aktiengesellschaft. Active years: 2008-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sonja Anlauf. Retrieved from https://idiyas.com/inventor/sonja-anlauf

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 47.1

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 10.0

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

Wuppertal, DE (2008 - 2015)
Wermelskirchen, DE (2011 - 2021)

Company Filing History:

6 out of 53

Aicuris Gmbh + Co. Kg.

patents

6 out of 721

Bayer Intellectual Property Gmbh

patents

5 out of 387

Bayer Pharma Aktiengesellschaft

patents

4. 1 out of 12,270

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2008-2021

Loading Chart...

Areas of Expertise:

mIDH1 Inhibitors

COPD Treatments

Benzimidazoles

Pyrimidine Derivatives

Nonadepsipeptides

Dihydropyrimidinones

Cyclic Peptides

Sulfonic Amides

Thioaryl Compounds

Tumor Treatment

Peptide Chemistry

Amine Derivatives

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11136296 - Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof (2021-10-05),

2. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors (2019-10-15),

3. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors (2018-11-27),

4. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors (2018-05-01),

5. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors (2018-04-24),

6. 9359362 - Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD (2016-06-07),

7. 9174997 - 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof (2015-11-03),

8. 8889700 - 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use (2014-11-18),

9. 8691817 - Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof (2014-04-08),

10. 8569314 - Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD (2013-10-29),

11. 8288402 - 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use (2012-10-16),

12. 8076285 - Lysobactin amides (2011-12-13),

13. 7786079 - Substituted nonadepsipeptides (2010-08-31),

14. 7727956 - Deoxonadepsipeptides (2010-06-01),

15. 7718611 - Cyclic nonapeptide amides (2010-05-18),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm here to assist you with the article about inventor Sonja Anlauf.

Title: The Innovative Works of Inventor Sonja Anlauf

Introduction:

Sonja Anlauf, a prolific inventor hailing from Wermelskirchen, Germany, has left a significant mark in the field of pharmaceutical innovations with a total of 17 patents to his name.

Latest Patents:

1. "Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof" - Anlauf's groundbreaking work focuses on novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, showing potential for the treatment and prevention of fibrotic and inflammatory disorders.

2. "Benzimidazol-2-amines as mIDH1 inhibitors" - Anlauf's invention of benzimidazol-2-amines holds promise in the treatment of neoplasms, showcasing his dedication to advancing medical solutions.

Career Highlights:

Having contributed his expertise to renowned companies like Bayer Intellectual Property GmbH and Aicuris GmbH & Co. KG, Anlauf has demonstrated his commitment to driving innovation in the pharmaceutical industry.

Collaborations:

Anlauf has had the privilege of collaborating with esteemed professionals in the field, including Franz Von Nussbaum and Dagmar Karthaus, highlighting his ability to work effectively within a team to achieve groundbreaking results.

Conclusion:

Inventor Sonja Anlauf's remarkable ingenuity and dedication to advancing pharmaceutical solutions have solidified his position as a trailblazer in the industry. His patents and collaborations stand as a testament to his relentless pursuit of innovation for the betterment of healthcare worldwide.

Profile summary based on public USPTO records.